Author: Ken Dropiewski

EOSOLUTIONS CORP. ANNOUNCES THE FULL COMMERCIAL LAUNCH OF THE DR. BANNER BALLOON GUIDE CATHETER: A BREAKTHROUGH BALLOON GUIDE CATHETER WITH UNMATCHED FEATURES FOR NEUROVASCULAR PROCEDURES

PEMBROKE PINES, Fla., May 24, 2023 /PRNewswire/ — EOSolutions Corp., a pioneering medical technology company focused on delivering high-quality catheter solutions, is proud to introduce the Dr. Banner, Balloon Guide Catheter (BGC). Developed in collaboration with InNeuroCo, a leading design, consulting, and contract manufacturing group, Dr. Banner sets new benchmarks in catheter technology, […]

Aerami Therapeutics Announces Pharmacokinetic Data Demonstrating the Potential of AER-901 (Inhaled Imatinib) to Achieve Therapeutic Levels at Low Inhaled Doses for Treatment of Pulmonary Hypertension

DURHAM, N.C., May 24, 2023 (GLOBE NEWSWIRE) — Aerami Therapeutics (“Aerami”), a clinical stage biopharmaceutical company dedicated to breathing life into the treatment of serious and rare cardiopulmonary conditions, today announced results from studies of AER-901 (inhaled imatinib) that support progression into a Phase 2 clinical trial in both pulmonary […]

Ardelyx, Inc. Reports Employment Inducement Grants

WALTHAM, Mass., May 23, 2023 (GLOBE NEWSWIRE) — Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that on May 22, 2023, the compensation committee of the company’s board of directors granted two new […]

Element Science Announces Completion of Enrollment in the Jewel IDE Study Evaluating the Jewel Patch Wearable Cardioverter Defibrillator (P-WCD)

Case study of patient save also presented at Heart Rhythm 2023 SAN FRANCISCO–(BUSINESS WIRE)–Element Science, an innovative health technology company pioneering a digital wearable platform for high-risk cardiovascular patients transitioning from hospital to home, announced the completion of enrollment in its Jewel IDE Study (NCT05201495). A case study was also […]

Microbot Medical Announces Closing of $2.66 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules

HINGHAM, Mass., May 24, 2023 (GLOBE NEWSWIRE) — Microbot Medical Inc. (Nasdaq: MBOT) today announced that it has closed its previously announced registered direct offering for the purchase and sale of 1,209,500 shares of the Company’s common stock (or common stock equivalents) at a purchase price of $2.20 per share […]

Endologix Announces 150th Patient Enrolled in JAGUAR Randomized Controlled Trial

JAGUAR Study Evaluates ALTO® Compared to Other Commercially Available EVAR Devices IRVINE, Calif.–(BUSINESS WIRE)–Endologix LLC, a privately held, global medical device company, dedicated to providing disruptive therapies for the interventional treatment of vascular disease, today announced the completion of the 150th case in the JAGUAR Study. This randomized controlled trial […]

Artivion Announces FDA PMA Approval of PerClot and Transfer of PMA to Baxter

Artivion to Receive $18.75 Million Milestone Payment Under Previously Announced Agreement Artivion to Begin Supplying Product to Baxter Under Transitional Manufacturing and Supply Agreement ATLANTA, May 23, 2023 /PRNewswire/ — Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that the U.S. Food and Drug Administration (FDA) granted premarket […]

Eko Health Recognized for Award-Winning AI Technology and Hybrid Workforce

For the second consecutive year, Eko Health honored with Fast Company’s World Changing Ideas Awards and Inc. Magazine’s Best Workplaces OAKLAND, Calif., May 23, 2023 /PRNewswire/ — Eko Health, a leading innovator in digital health technology for heart and lung disease detection, today announced that it has been honored in Fast Company’s World Changing […]

89bio Initiates Phase 3 ENTRUST Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia (SHTG)

First FGF21 analog to enter Phase 3 development SAN FRANCISCO, May 23, 2023 (GLOBE NEWSWIRE) — 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced the initiation of ENTRUST, a Phase 3 […]